Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Irish Pharmaceutical Company Elan to “Reinvent Itself”

By BiotechDaily International staff writers
Posted on 18 Feb 2013
A major restructuring of the Tysabri collaboration between Elan Corporation (Elan; Dublin, Ireland) and Biogen Idec (Weston, MA, USA) will release Elan from reliance on one single asset and allow diversification to other fields.

Under the terms of the agreement, Elan will withdraw from the current equal-share collaboration, leaving Biogen Idec with full ownership of the blockbuster multiple sclerosis (MS) treatment Tysabri, and receiving in return an upfront payment of USD 3.25 billion and a double digit tiered royalty structure on future sales. While the agreement gives Elan strategic flexibility to buy new assets and expand to other fields, it leaves its future performance unclear, since Tysabri was by far its most important product, responsible for almost all its revenue.

For Biogen, the deal improves its standing in the MS arena, as it hopes to win approval for BG-12, a new drug to treat the debilitating neurological disease it expects to become a leading treatment for MS after its planned second-quarter 2013 introduction. Biogen will then be able to offer BG-12 alongside Tysabri and another MS treatment called Avonex, both of which are given by intravenous (IV injection), thus providing a range of treatment options for patients. Rival providers of MS treatments include Novartis, Teva Pharmaceuticals (Petach Tikva, Israel), Merck KGaA, and Bayer.

“This transaction enables Elan and its shareholders to realize, upon close, a meaningful percentage of the current value of Tysabri, while maintaining long term cash flow realization through the multitiered royalty structure of the complete asset,” said Kelly Martin, CEO of Elan. “Our motivation was to diversify and de-risk the company to move forward; and for the patients to continue to benefit from the profound efficacy of Tysabri. The risk of one asset and a single collaborator was not ideal.”

“The restructuring of this business collaboration provides Elan with significant strategic flexibility. Future actions will be guided by our consistent and multiyear approach of dynamic risk/reward assessment of business opportunities,” added Mr. Martin. “We are enthusiastic about the market opportunities around the globe and remain flexible and creative about the manner in which we would participate in those opportunities.”

Tysabri (natalizumab) is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, used in the treatment of MS and Crohn's disease. It is administered by IV infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier (BBB). It has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, and cognitive decline, as well as significantly improving quality of life in people and increasing rates of remission and preventing relapse in Crohn's disease.

Related Links:

Elan Corporation
Biogen Idec




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.